Metastatic renal cell carcinoma of the native kidney in a renal transplant recipient: Revisiting the era of tyrosine kinase inhibitors – Case report

Patients who receive solid organ transplants are at higher risk for developing cancer, which is attributable to chronic immune suppression. Less than 8 cases of metastatic RCC (mRCC) have been reported until now. The aim of this article is to present the case of a 77-year-old male with mRCC of the n...

Descripción completa

Detalles Bibliográficos
Autores principales: Suso-Palau, Daniel, Chavarriaga, Julián, Usubillaga, Francisco, Asprilla, Josué, Micolta, Lina, Urrego, Marcela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036129/
https://www.ncbi.nlm.nih.gov/pubmed/35480854
http://dx.doi.org/10.1016/j.eucr.2022.102082
Descripción
Sumario:Patients who receive solid organ transplants are at higher risk for developing cancer, which is attributable to chronic immune suppression. Less than 8 cases of metastatic RCC (mRCC) have been reported until now. The aim of this article is to present the case of a 77-year-old male with mRCC of the native kidney and discuss treatment options including targeted therapy, which appears to be the treatment of choice, even in the era of immunotherapy.

Ejemplares similares